A Single-center, Single-arm, Phase Ib Clinical Study of the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05497076

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:39:02.183536+00:00

Published At

2022-08-11T00:00:00+00:00

Record Updated At

2022-08-11

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology", "The TNM (8th) Phase is IV", "With EGFR Mutations", "Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment", "Male or Female", "The Age of 18 Years Old or More", "ECOG PS 0 to 2 Points"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2022-08-11"

protocolSection.identificationModule.nctId

"NCT05497076"

protocolSection.identificationModule.officialTitle

"A Single-center, Single-arm, Phase Ib Clinical Study of the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy"

protocolSection.statusModule.overallStatus

"UNKNOWN"

protocolSection.designModule.phases

[]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology (protocolSection.conditionsModule.conditions)
• The TNM (8th) Phase is IV (protocolSection.conditionsModule.conditions)
• With EGFR Mutations (protocolSection.conditionsModule.conditions)
• Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment (protocolSection.conditionsModule.conditions)
• Male or Female (protocolSection.conditionsModule.conditions)
• The Age of 18 Years Old or More (protocolSection.conditionsModule.conditions)
• ECOG PS 0 to 2 Points (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.